---
document_datetime: 2025-11-25 11:47:11
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tysabri-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tysabri-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.5734353
conversion_datetime: 2025-12-29 19:35:20.959307
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tysabri

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | This was an application for a group of | 25/11/2025                          |                                             | Annex II                         |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000314074                     | variations. A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release -   |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000262419 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 02/10/2025 | SmPC, Annex II, Labelling and PL SmPC section 4.4 is updated to inform that data from an observational study demonstrated that there is no increased risk of PML for the group of patients switching to natalizumab from fingolimod, dimethyl fumarate, or teriflunomide when compared to the group of patients switching from either beta interferon or glatiramer acetate and that no information is available for other disease-modifying therapies. SmPC section 4.8 is updated to remove |

<div style=\"page-break-after: always\"></div>

| C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted A grouped application consisting of: C.I.4: Update of sections 4.4 of the SmPC in order to update a warning about PML in patients with prior treatment with immunosuppressive or immunomodulatory therapies based on final results from study 101MS411, listed as a category 3 study in the RMP; this is an observational study utilising data from the US Tysabri TOUCH programme and select EU MS registries to estimate the risk of progressive multifocal leukoencephalopathy (PML) and other serious opportunistic infections among patients who were exposed to an MS disease modifying treatment prior to treatment with Tysabri. C.I.4: Update of sections 4.8 and 5.1 of the SmPC in order to update safety and pharmacodynamic information based on final results from study IMA 06 02 (TOP) listed as a category 3 study in the RMP. This is an observational study to evaluate the long-term safety and impact on disease activity and progression of Tysabri as a single disease-modifying agent in patients   | information on malignancies SmPC section 5.1 is updated to include a high-level summary of the design and main study results of the Tysabri Observational Program (TOP, IMA-06-02) Study For more information, please refer to the Summary of Product Characteristics.   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | with RRMS in a clinical practice setting. The RMP version 34.0 has also been adopted. Changes are also made to the PI to bring it in line with the current QRD template version. In addition, the list of local representatives in the PL is being revised.                                                                                                         |            |     |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| Variation type II / EMA/VR/0000268214 | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.f Change outside the approved specifications limits range for the active substance - Accepted                                                                   | 17/07/2025 |     | N/A |
| Variation type IB / EMA/VR/0000258487 | B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.z Other changes - Accepted                                                                                                                                                                                                                   | 16/04/2025 | N/A |     |
| Variation type IB / EMA/VR/0000261321 | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of | 15/04/2025 | N/A |     |

<div style=\"page-break-after: always\"></div>

the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted

B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted